Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 2013, 639468

The Possible Potential Therapeutic Targets for Drug Induced Gingival Overgrowth


The Possible Potential Therapeutic Targets for Drug Induced Gingival Overgrowth

Tamilselvan Subramani et al. Mediators Inflamm.


Gingival overgrowth is a side effect of certain medications. The most fibrotic drug-induced lesions develop in response to therapy with phenytoin, the least fibrotic lesions are caused by cyclosporin A, and the intermediate fibrosis occurs in nifedipine-induced gingival overgrowth. Fibrosis is one of the largest groups of diseases for which there is no therapy but is believed to occur because of a persistent tissue repair program. During connective tissue repair, activated gingival fibroblasts synthesize and remodel newly created extracellular matrix. Proteins such as transforming growth factor (TGF), endothelin-1 (ET-1), angiotensin II (Ang II), connective tissue growth factor (CCN2/CTGF), insulin-like growth factor (IGF), and platelet-derived growth factor (PDGF) appear to act in a network that contributes to the development of gingival fibrosis. Since inflammation is the prerequisite for gingival overgrowth, mast cells and its protease enzymes also play a vital role in the pathogenesis of gingival fibrosis. Drugs targeting these proteins are currently under consideration as antifibrotic treatments. This review summarizes recent observations concerning the contribution of TGF-β, CTGF, IGF, PDGF, ET-1, Ang II, and mast cell chymase and tryptase enzymes to fibroblast activation in gingival fibrosis and the potential utility of agents blocking these proteins in affecting the outcome of drug-induced gingival overgrowth.


Figure 1
Figure 1
Schematic diagram of interplay among profibrotic mediators. These proteins promote fibroblast activation and gingival fibrosis. Ang II: angiotensin II; CTGF: connective tissue growth factor; ET: endothelin; IGF: insulin-like growth factor; PDGF: platelet-derived growth factor; TGF: transforming growth factor; ECM: extracellular matrix.
Figure 2
Figure 2
Potential role of angiotensin II and its receptors expressed by fibroblast in gingival fibrosis. Ang II: angiotensin II; AT: angiotensin receptor; ACE: angiotensin-converting enzyme; ECM: extracellular matrix.
Figure 3
Figure 3
Potential role of endothelin-1 and its receptors expressed by fibroblast in gingival fibrosis. ET-1: endothelin-1; ETA: endothelin receptor A; ETB: endothelin receptor B; ECM: extracellular matrix.

Similar articles

See all similar articles

Cited by 6 PubMed Central articles

See all "Cited by" articles


    1. Seymour RA. Calcium channel blockers and gingival overgrowth. British Dental Journal. 1991;170(10):376–379. - PubMed
    1. Miller CS, Damm DD. Incidence of verapamil-induced gingival hyperplasia in a dental population. Journal of Periodontology. 1992;63(5):453–456. - PubMed
    1. Nishikawa S, Nagata T, Morisaki I, Oka T, Ishida H. Pathogenesis of drug-induced gingival overgrowth. A review of studies in the rat model. Journal of Periodontology. 1996;67(5):463–471. - PubMed
    1. Ellis JS, Seymour RA, Steele JG, Robertson P, Butler TJ, Thomason JM. Prevalence of gingival overgrowth induced by calcium channel blockers: a community-based study. Journal of Periodontology. 1999;70(3):63–67. - PubMed
    1. Perlik F, Kolinova M, Zvarova J, Patzelova V. Phenytoin as a risk factor in gingival hyperplasia. Therapeutic Drug Monitoring. 1995;17(5):445–448. - PubMed

MeSH terms


LinkOut - more resources